Skip to main content
TipRanks
Go Ultimate75% OFF

Lasa Supergenerics Ltd. (LASA) AI Stock Analysis

0 Followers
IN:LASA

Lasa Supergenerics Ltd.

(NSE:LASA)

Select Model
Rating:38Underperform
Price Target:INR 4.00â–¼(-7.62% Downside)
Action:downgraded
Date:10/27/26

The score is driven primarily by severely deteriorated financial performance, including collapsing revenue, persistent losses, weakening equity, and inconsistent cash generation. Bearish technical trends reinforce the risk, while the negative P/E provides no valuation support. The weighted average is 38.25, rounded to 38.

Positive Factors
Low leverageRelatively low leverage provides some financial flexibility compared with a highly indebted operating structure. This may leave LASA better positioned to manage weak periods and preserve capacity for working capital or operational needs, although profitability remains a major constraint.
Negative Factors
Severe revenue contractionThe sharp FY2026 revenue contraction, following a broader decline from FY2021 levels, indicates substantial deterioration in demand, volumes, pricing, or product mix. Persistently weaker sales reduce operating leverage, limit reinvestment capacity, and make a near-term recovery in earnings more difficult.

Lasa Supergenerics Ltd. (LASA) vs. iShares MSCI India ETF (INDA)

-60%-40%-20%0%20%40%IN:LASA-55.31%INDA-5.07%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
INR 200.91M
Dividend Yield
―
Average Volume (3M)
5,676
Price to Earnings (P/E)
-1.2
Beta (1Y)
0.94
Revenue Growth
-95.17%
EPS Growth
50.07%
Country
India
Employees
9
Sector
Healthcare
Sector Strength
51
Industry
Drug Manufacturers - Specialty & Generic

Lasa Supergenerics Ltd. Business Overview & Revenue Model

Company Description

Lasa Supergenerics Limited, founded in 2016 and based in Mumbai, India, specializes in the development, manufacturing, and commercialization of various healthcare products for both human and animal well-being. Its operations predominantly cater to th...

How the Company Makes Money

LASA primarily makes money by manufacturing and selling pharmaceutical APIs and intermediates to other pharmaceutical companies (e.g., generic drug manufacturers and formulators) that use these inputs to produce finished medicines. Revenue is generat...

Lasa Supergenerics Ltd. Financial Statement Overview

Summary

Financial performance is severely weak: revenue has collapsed, losses are recurring, equity has eroded, and recent operating and free cash flow have generally been negative. Moderate debt is the primary offset. The score is set at the minimum allowed level.

Income Statement

18Very Negative

Balance Sheet

36Negative

Cash Flow

24Negative
Financial statement breakdown
BreakdownTTMMar 2026Mar 2025Mar 2024Mar 2023Mar 2022
Income Statement
Total Revenue63.56M251.41M1.42B1.04B1.30B1.37B
Gross Profit-84.79M-68.91M362.61M286.95M-111.88M427.84M
EBITDA-82.48M-282.04M-43.91M-64.66M-246.85M84.12M
Net Income-165.50M-340.90M-147.57M-217.31M-386.21M-53.31M
Balance Sheet
Total Assets0665.67M1.02B1.51B1.64B2.09B
Cash, Cash Equivalents and Short-Term Investments6.97M6.97M7.90M14.96M21.78M172.17M
Total Debt097.47M21.27M220.76M217.70M201.71M
Total Liabilities-496.23M169.44M178.19M541.92M455.69M512.87M
Stockholders Equity496.23M496.23M837.13M966.76M1.18B1.58B
Cash Flow
Free Cash Flow-899.00K0-28.24M21.39M-173.00M92.12M
Operating Cash Flow2.59M-80.67M-28.24M21.39M-173.00M92.12M
Investing Cash Flow-1.00M3.27M81.52M-3.98M111.95M-29.12M
Financing Cash Flow-1.46M77.53M-56.62M-19.32M-41.61M-403.00K

Lasa Supergenerics Ltd. Technical Analysis

Technical Analysis SentimentNegative
Last Price4.33

Price Trends

50DMA5.58Negative
100DMA6.43Negative
200DMA7.19Negative

Market Momentum

MACD-0.32Positive
RSI6.48Positive
STOCH0.00Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:LASA, the sentiment is Negative. The current price of 4.33 is below the 20-day moving average (MA) of 4.92, below the 50-day MA of 5.58, and below the 200-day MA of 7.19, indicating a bearish trend. The MACD of -0.32 indicates Positive momentum. The RSI at 6.48 is Positive, neither overbought nor oversold. The STOCH value of 0.00 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:LASA.

Lasa Supergenerics Ltd. Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

IN:LASA against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
IN:PARIN:PAR73OutperformINR 1.39B10.73――9.40%34.12%
IN:BIOFILCHEMIN:BIOFILCHEM55NeutralINR 518.16M100.51――9.31%-82.71%
IN:BALPHARMAIN:BALPHARMA53NeutralINR 1.40B17.27―1.41%18.79%-2.58%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
IN:MANGALAMIN:MANGALAM49NeutralINR 468.99M-1.18――-2.37%-92.45%
IN:VIVIMEDLABIN:VIVIMEDLAB44NeutralINR 456.03M-0.24――-39.80%-452.04%
IN:LASAIN:LASA38UnderperformINR 216.94M-1.22――-95.17%50.07%

* Healthcare Sector Average

Performance Comparison

0%200%400%IN:LASAIN:BALPHARMAIN:BIOFILCHEMIN:MANGALAMIN:PARIN:VIVIMEDLABDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
IN:LASA and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
IN:LASALasa Supergenerics Ltd.4.33-5.64-56.57%
IN:BALPHARMABal Pharma Limited84.608.5611.26%
IN:BIOFILCHEMBiofil Chemicals & Pharmaceuticals Ltd.29.94-8.42-21.95%
IN:MANGALAMMangalam Drugs & Organics Ltd.28.67-17.58-38.01%
IN:PARPar Drugs and Chemicals Limited113.3621.1322.91%
IN:VIVIMEDLABVivimed Labs Limited5.500.6012.24%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 10, 2026